MYCL and osteoporosis: Collectively, our findings define a novel Sgk1-Stat3-Mycl-Ctsk signaling axis that contributes to osteoclastogenesis and suggest that Sgk1 inhibition represent a potential therapeutic strategy for osteoporosis.